Novartis AGNVSNYSE
Loading
Income Before Tax Over TimeExpanding
Percentile Rank93
3Y CAGR+31.8%
5Y CAGR+10.7%
Studio
Year-over-Year Change

Pre-tax earnings

3Y CAGR
+31.8%/yr
vs -15.5%/yr prior
5Y CAGR
+10.7%/yr
Recent acceleration
Acceleration
+47.3pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.7x
Solid growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$16.44B+20.5%
2024$13.64B+49.5%
2023$9.12B+27.1%
2022$7.18B-70.7%
2021$24.53B+148.3%
2020$9.88B+10.5%
2019$8.94B-36.6%
2018$14.10B+54.9%
2017$9.10B+16.4%
2016$7.82B-